Esbenshade T A, Hirasawa A, Tsujimoto G, Tanaka T, Yano J, Minneman K P, Murphy T J
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Mol Pharmacol. 1995 May;47(5):977-85.
We have cloned the human alpha 1d-adrenergic receptor (AR) and compared the pharmacological properties of the three recombinant human alpha 1-AR subtypes in SK-N-MC cells. SK-N-MC cells natively express a mixture of alpha 1-AR subtypes, and the use of an inducible expression system allowed us to directly compare the recombinant and native subtypes without concern for cell-specific processing or microenvironment. The human alpha 1d-AR was expressed from a cDNA/gene fusion construct cloned from human SK-N-MC cell cDNA and human genomic libraries. This receptor is deduced to contain 572 amino acids with 98% identity to the rat alpha 1d-AR in the transmembrane domains and, when expressed in human embryonic kidney 293 cells, has alpha 1-AR binding properties similar to those of the rat alpha 1d-AR. Norepinephrine increased inositol phosphate formation and mobilized intracellular Ca2+ in transfected 293 cells. Reverse transcription-polymerase chain reaction analysis of the three cloned human subtypes (alpha 1a, alpha 1b, and alpha 1d) in mRNA from SK-N-MC cells, which natively express alpha 1A- and alpha 1B-like pharmacology, showed abundant alpha 1a and alpha 1d but fewer alpha 1b transcripts. The three human clones were expressed in SK-N-MC cells using isopropyl-beta-D-thiogalactoside-inducible vectors. Upon induction, alpha 1-AR density was increased with the recombinant subtype comprising 67-80% of total alpha 1-ARs. Inhibition curves for (+)-niguldipine and 5-methylurapidil fit best to a two-site model in uninduced cells, indicating significant receptor heterogeneity. Isopropyl-beta-D-thiogalactoside induction altered the potencies of both compounds, causing most inhibition curves to fit best to a one-site model. (+)-Niguldipine was 100-fold more potent at the alpha 1a-AR than at alpha 1b- or alpha 1d-ARs, whereas 5-methylurapidil had similar potencies at alpha 1a- and alpha 1d-ARs and about 10-fold lower affinity at the alpha 1b-AR. We conclude that the complex alpha 1A- and alpha 1B-like pharmacology observed in native SK-N-MC cells is due to expression of all three subtypes in different proportions, independently of cell-specific processing or environmental factors, and that the alpha 1a-AR cDNA encodes the pharmacologically defined alpha 1A subtype.
我们克隆了人α1d - 肾上腺素能受体(AR),并比较了三种重组人α1 - AR亚型在SK - N - MC细胞中的药理学特性。SK - N - MC细胞天然表达多种α1 - AR亚型的混合物,使用诱导表达系统使我们能够直接比较重组亚型和天然亚型,而无需担心细胞特异性加工或微环境。人α1d - AR由从人SK - N - MC细胞cDNA和人基因组文库克隆的cDNA/基因融合构建体表达。该受体推断含有572个氨基酸,在跨膜结构域与大鼠α1d - AR有98%的同一性,当在人胚肾293细胞中表达时,具有与大鼠α1d - AR相似的α1 - AR结合特性。去甲肾上腺素增加了转染的293细胞中肌醇磷酸的形成并动员了细胞内Ca2+。对天然表达α1A - 和α1B - 样药理学的SK - N - MC细胞mRNA中的三种克隆人亚型(α1a、α1b和α1d)进行逆转录 - 聚合酶链反应分析,结果显示α1a和α1d转录本丰富,而α1b转录本较少。使用异丙基 - β - D - 硫代半乳糖苷诱导型载体在SK - N - MC细胞中表达这三种人克隆体。诱导后,α1 - AR密度增加,重组亚型占总α1 - AR的67 - 80%。在未诱导的细胞中,(+) - 尼群地平(niguldipine)和5 - 甲基乌拉地尔(5 - methylurapidil)的抑制曲线最适合双位点模型,表明存在明显的受体异质性。异丙基 - β - D - 硫代半乳糖苷诱导改变了两种化合物的效力,使大多数抑制曲线最适合一位点模型。(+) - 尼群地平对α1a - AR的效力比对α1b - 或α1d - AR高100倍,而5 - 甲基乌拉地尔对α1a - 和α1d - AR的效力相似,对α1b - AR的亲和力低约10倍。我们得出结论,在天然SK - N - MC细胞中观察到的复杂的α1A - 和α1B - 样药理学是由于所有三种亚型以不同比例表达,与细胞特异性加工或环境因素无关,并且α1a - AR cDNA编码药理学定义的α1A亚型。